Medtronic (MDT) EBITDA (2014 - 2026)

Medtronic has disclosed EBITDA across 13 years of filings, most recently posting $1.5 billion for Q1 2026.

• EBITDA for Q1 2026 came in at $1.5 billion, down 11.06% year-over-year; the trailing twelve-month figure through Jan 2026 was $6.0 billion (up 8.24% YoY), and the FY2025 annual result was $6.0 billion, up 15.77% from the prior year.
• EBITDA came in at $1.5 billion for Q1 2026 at Medtronic, down from $1.7 billion in the prior quarter.
• In the past five years, EBITDA ranged from a high of $1.7 billion in Q4 2025 to a low of $1.1 billion in Q2 2024.
• The 5-year median for EBITDA is $1.4 billion (2025), against an average of $1.4 billion.
• Across the five-year window, EBITDA sank 32.72% in 2024 and surged 36.37% in 2025, its largest moves.
• Medtronic's EBITDA stood at $1.4 billion in 2022, then dropped by 4.56% to $1.3 billion in 2023, then climbed by 19.03% to $1.6 billion in 2024, then gained by 5.71% to $1.7 billion in 2025, then retreated by 13.17% to $1.5 billion in 2026.
• The last three EBITDA figures came in at $1.5 billion (Q1 2026), $1.7 billion (Q4 2025), and $1.4 billion (Q3 2025), per Business Quant data.